ARTL vs. SNGX, ENSC, ZVSA, LIPO, CING, HILS, GNPX, THAR, SEEL, and CPHI
Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Soligenix (SNGX), Ensysce Biosciences (ENSC), ZyVersa Therapeutics (ZVSA), Lipella Pharmaceuticals (LIPO), Cingulate (CING), Hillstream BioPharma (HILS), Genprex (GNPX), Tharimmune (THAR), Seelos Therapeutics (SEEL), and China Pharma (CPHI). These companies are all part of the "pharmaceutical preparations" industry.
Soligenix (NASDAQ:SNGX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
Soligenix currently has a consensus price target of $3.00, suggesting a potential upside of 650.00%. Artelo Biosciences has a consensus price target of $5.00, suggesting a potential upside of 281.68%. Given Artelo Biosciences' higher possible upside, analysts clearly believe Soligenix is more favorable than Artelo Biosciences.
Soligenix has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Artelo Biosciences has a net margin of 0.00% compared to Artelo Biosciences' net margin of -731.94%. Soligenix's return on equity of -61.68% beat Artelo Biosciences' return on equity.
3.6% of Soligenix shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 1.4% of Soligenix shares are held by insiders. Comparatively, 6.9% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Soligenix received 241 more outperform votes than Artelo Biosciences when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 72.55% of users gave Artelo Biosciences an outperform vote.
Soligenix has higher revenue and earnings than Artelo Biosciences. Soligenix is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Soligenix and Soligenix both had 2 articles in the media. Soligenix's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.04 indicating that Artelo Biosciences is being referred to more favorably in the news media.
Summary
Soligenix beats Artelo Biosciences on 9 of the 15 factors compared between the two stocks.
Get Artelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artelo Biosciences Competitors List
Related Companies and Tools
